FINWIRES · TerminalLIVE
FINWIRES

$SOPH

5 stories mentioning SOPHUpdated 40d ago

Every FINWIRES story that references SOPH, newest first.

What are analysts saying about SOPH?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on SOPH?

Wire

AstraZeneca Collaborates With Sophia Genetics on Companion Diagnostics for Oncology Therapies

AstraZeneca (AZN) has entered into a multi-year global collaboration with Sophia Genetics (SOPH) aiming to advance the development and commercialization of two companion diagnostic programs supporting precision oncology therapies, Sophia Genetics said Tuesday.The collaboration will bring Sophia Genetics' decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies, according to a statement.Financial terms of the collaboration were not provided.Price: $157.64, Change: $-0.33, Percent Change: -0.21%

$AZN$SOPH
Insider Trading

Sophia Genetics Insider Sold Shares Worth $286,099, According to a Recent SEC Filing

Jurgi Camblong, Director, Executive Chairman, on July 20, 2026, sold 44,381 shares in Sophia Genetics (SOPH) for $286,099. Following the Form 4 filing with the SEC, Camblong has control over a total of 3,492,822 ordinary shares of the company, with 3,492,822 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1840706/000184070626000263/xslF345X05/wk-form4_1784750500.xml

$SOPH
Research

HC Wainwright Initiates SOPHiA GENETICS at Buy With $12 Price Target

SOPHiA GENETICS SA (SOPH) has an average rating of buy and mean price target of $9, according to analysts polled by FactSet.

$SOPH
Insider Trading

Sophia Genetics Insider Sold Shares Worth $506,690, According to a Recent SEC Filing

Jurgi Camblong, Director, Executive Chairman, on June 29, 2026, sold 83,679 shares in Sophia Genetics (SOPH) for $506,690. Following the Form 4 filing with the SEC, Camblong has control over a total of 3,581,293 ordinary shares of the company, with 3,581,293 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1840706/000184070626000237/xslF345X05/wk-form4_1782936197.xml

$SOPH
Insider Trading

Sophia Genetics Insider Sold Shares Worth $298,155, According to a Recent SEC Filing

Jurgi Camblong, Director, Chief Executive Officer, on June 25, 2026, sold 51,442 shares in Sophia Genetics (SOPH) for $298,155. Following the Form 4 filing with the SEC, Camblong has control over a total of 3,601,493 ordinary shares of the company, with 3,601,493 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1840706/000184070626000235/xslF345X05/wk-form4_1782763676.xml

$SOPH

Track with the FINWIRES app suite

FolioX
FolioX
Track SOPH in your portfolio
WheelAI
WheelAI
Analyze SOPH options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SOPH